Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

Clinical trial NCT01488097 · COMPLETED

Trial details

NCT number

NCT01488097

Sponsor

Alexion Pharmaceuticals, Inc.

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2011-12-12

Primary completion

2017-06-21

Enrollment

8

View on ClinicalTrials.gov